Rokos Capital Management (UK)’s Royalty Pharma RPRX Stock Holding History

Rokos Capital Management (UK)’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,106,813	Closed	-$29.6M	–	110
2023 Q3	$29.6M	Sell	1,106,813 -225,000	-17%	-$6.68M	0.22%	49
2023 Q2	$41M	Buy	1,331,813 +225,000	+20%	+$7.62M	0.4%	32
2023 Q1	$40.1M	Buy	1,106,813 +614,585	+125%	+$22.8M	2.96%	12
2022 Q4	$19.3M	Hold	492,228	–	–	0.85%	24
2022 Q3	$19.9M	Hold	492,228	–	–	0.59%	36
2022 Q2	$20.6M	Buy	+492,228	New	+$20.2M	0.6%	35
2021 Q3	–	Sell	-333,778	Closed	-$13.7M	–	146
2021 Q2	$13.7M	Buy	+333,778	New	+$14.2M	0.27%	47

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rokos Capital Management (UK)'s RPRX Position: Q4 2023 in Review

Rokos Capital Management (UK) sold out of Royalty Pharma (RPRX) in Q4 2023, closing a stake of 1,106,813 shares — an estimated $29.6M sold.

Rokos Capital Management (UK) first reported a position in RPRX in Q2 2021 and held it in 7 quarters. The position peaked at $41M in Q2 2023. 363 funds tracked by Wall St. Rank hold RPRX as of Q4 2023.

Rokos Capital Management (UK) reported no remaining Royalty Pharma position as of Q4 2023 after selling out during the quarter.
Rokos Capital Management (UK) sold 1,106,813 Royalty Pharma shares in Q4 2023, an estimated $29.6M.
Rokos Capital Management (UK) first reported a position in Royalty Pharma in Q2 2021 and held it in 7 quarters.
Rokos Capital Management (UK)'s Royalty Pharma position peaked at $41M in Q2 2023.
363 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2023.

Based on Rokos Capital Management (UK)'s 13F filing for Q4 2023, filed 14 Feb 2024.